The goal of this analysis is to demonstrate an estimation framework that estimates Poisson-Gamma model parameters of Phase-III trials by leveraging data from multiple public trials using a maximum likelihood approach.
No takes yet. Share an insight, caveat, or question.
Ninh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: